Based on the Ligand Pharmaceuticals Incorporated stock forecast from 5 analysts, the average analyst target price for Ligand Pharmaceuticals Incorporated is USD 134.75 over the next 12 months. Ligand Pharmaceuticals Incorporated’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Ligand Pharmaceuticals Incorporated is Neutral, which is based on 7 positive signals and 6 negative signals. At the last closing, Ligand Pharmaceuticals Incorporated’s stock price was USD 119.19. Ligand Pharmaceuticals Incorporated’s stock price has changed by +6.70% over the past week, +7.39% over the past month and +98.35% over the last year.
No recent analyst target price found for Ligand Pharmaceuticals Incorporated
No recent average analyst rating found for Ligand Pharmaceuticals Incorporated
Company Overview Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida. Read Less
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparagi...Read More
Frequently Asked Questions About Ligand Pharmaceuticals Incorporated (LGND) Stock
Based on ratings from 5 analysts Ligand Pharmaceuticals Incorporated's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 8 buy, sell and hold ratings.
Unfortunately we do not have enough data on LGND's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for LGND is USD 134.75 over the next 12 months. The maximum analyst target price is USD 157 while the minimum anlayst target price is USD 95.
LGND stock's Price/Earning ratio is 44.86.
Our analysis grades LGND stock's Price / Earning ratio at F. This means that LGND stock's Price/Earning ratio is above 83% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this LGND may be a overvalued for its sector.
The last closing price of LGND's stock was USD 119.19.
The most recent market capitalization for LGND is USD 2.11B.
Based on targets from 5 analysts, the average taret price for LGND is projected at USD 134.75 over the next 12 months.
This means that LGND's stock price may go up by +13.05% over the next 12 months.
We can't find any ETFs which contains Ligand Pharmaceuticals Incorporated's stock.
As per our most recent records Ligand Pharmaceuticals Incorporated has 58 Employees.
Ligand Pharmaceuticals Incorporated's registered address is 555 Heritage Drive, Jupiter, FL, United States, 33458.
You can get more information about it from Ligand Pharmaceuticals Incorporated's website at https://www.ligand.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Ligand Pharmaceuticals Incorporated (LGND) Stock
Based on ratings from 5 analysts Ligand Pharmaceuticals Incorporated's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 8 buy, sell and hold ratings.
Unfortunately we do not have enough data on LGND's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for LGND is USD 134.75 over the next 12 months. The maximum analyst target price is USD 157 while the minimum anlayst target price is USD 95.
LGND stock's Price/Earning ratio is 44.86.
Our analysis grades LGND stock's Price / Earning ratio at F. This means that LGND stock's Price/Earning ratio is above 83% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this LGND may be a overvalued for its sector.
The last closing price of LGND's stock was USD 119.19.
The most recent market capitalization for LGND is USD 2.11B.
Based on targets from 5 analysts, the average taret price for LGND is projected at USD 134.75 over the next 12 months.
This means that LGND's stock price may go up by +13.05% over the next 12 months.
We can't find any ETFs which contains Ligand Pharmaceuticals Incorporated's stock.
As per our most recent records Ligand Pharmaceuticals Incorporated has 58 Employees.
Ligand Pharmaceuticals Incorporated's registered address is 555 Heritage Drive, Jupiter, FL, United States, 33458.
You can get more information about it from Ligand Pharmaceuticals Incorporated's website at https://www.ligand.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for LGND !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
